Search research articles
Contact Us
Filters
Showing results (111-120 of 123) with videos related to
Page
of 13
Sort By:
The Journal of Biological Chemistry
|
April 17, 2001
Histone hyperacetylation induced by histone deacetylase inhibitors is not sufficient to cause growth inhibition in human dermal fibroblasts
H Brinkmann, A L Dahler, C Popa, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1990
Genotoxicity and cell cycle effects of platinum-based imaging agents in cisplatin-resistant human tumour cells
J Lean, P G Parsons, A B Awaluddin, et al.
Cancer Research
|
November 14, 1997
CDKN2A/p16 is inactivated in most melanoma cell lines
M Castellano, P M Pollock, M K Walters, et al.
Biochemical Pharmacology
|
June 1, 1997
Serine protease inhibition and mitochondrial dysfunction associated with cisplatin resistance in human tumor cell lines: targets for therapy
Y Dong, S J Berners-Price, D R Thorburn, et al.
Genomics
|
September 1, 1995
Chromosomal structure of the human TYRP1 and TYRP2 loci and comparison of the tyrosinase-related protein gene family
R A Sturm, B J O'Sullivan, N F Box, et al.
Molecular Pharmacology
|
September 20, 2001
Up-regulation of p21(WAF1/CIP1) by histone deacetylase inhibitors reduces their cytotoxicity
A J Burgess, S Pavey, R Warrener, et al.
International Journal of Cancer
|
August 22, 1997
Reduced expression of retinoblastoma gene product (pRB) and high expression of p53 are associated with poor prognosis in ovarian cancer
Y Dong, M D Walsh, M A McGuckin, et al.
International Journal of Cancer
|
February 20, 1997
Increased expression of cyclin-dependent kinase inhibitor 2 (CDKN2A) gene product P16INK4A in ovarian cancer is associated with progression and unfavourable prognosis
Y Dong, M D Walsh, M A McGuckin, et al.
The Journal of Investigative Dermatology
|
February 17, 2001
Melanocortin-1 receptor genotype is a risk factor for basal and squamous cell carcinoma
N F Box, D L Duffy, R E Irving, et al.
Biochemical Pharmacology
|
June 1, 1997
Tumor selectivity and transcriptional activation by azelaic bishydroxamic acid in human melanocytic cells
P G Parsons, C Hansen, D P Fairlie, et al.
Page
of 13
Search research articles
Search
Showing results (111-120 of 123) with videos related to
Sort By:
Page
of 13
The Journal of Biological Chemistry
|
April 17, 2001
Histone hyperacetylation induced by histone deacetylase inhibitors is not sufficient to cause growth inhibition in human dermal fibroblasts
H Brinkmann, A L Dahler, C Popa, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1990
Genotoxicity and cell cycle effects of platinum-based imaging agents in cisplatin-resistant human tumour cells
J Lean, P G Parsons, A B Awaluddin, et al.
Cancer Research
|
November 14, 1997
CDKN2A/p16 is inactivated in most melanoma cell lines
M Castellano, P M Pollock, M K Walters, et al.
Biochemical Pharmacology
|
June 1, 1997
Serine protease inhibition and mitochondrial dysfunction associated with cisplatin resistance in human tumor cell lines: targets for therapy
Y Dong, S J Berners-Price, D R Thorburn, et al.
Genomics
|
September 1, 1995
Chromosomal structure of the human TYRP1 and TYRP2 loci and comparison of the tyrosinase-related protein gene family
R A Sturm, B J O'Sullivan, N F Box, et al.
Molecular Pharmacology
|
September 20, 2001
Up-regulation of p21(WAF1/CIP1) by histone deacetylase inhibitors reduces their cytotoxicity
A J Burgess, S Pavey, R Warrener, et al.
International Journal of Cancer
|
August 22, 1997
Reduced expression of retinoblastoma gene product (pRB) and high expression of p53 are associated with poor prognosis in ovarian cancer
Y Dong, M D Walsh, M A McGuckin, et al.
International Journal of Cancer
|
February 20, 1997
Increased expression of cyclin-dependent kinase inhibitor 2 (CDKN2A) gene product P16INK4A in ovarian cancer is associated with progression and unfavourable prognosis
Y Dong, M D Walsh, M A McGuckin, et al.
The Journal of Investigative Dermatology
|
February 17, 2001
Melanocortin-1 receptor genotype is a risk factor for basal and squamous cell carcinoma
N F Box, D L Duffy, R E Irving, et al.
Biochemical Pharmacology
|
June 1, 1997
Tumor selectivity and transcriptional activation by azelaic bishydroxamic acid in human melanocytic cells
P G Parsons, C Hansen, D P Fairlie, et al.
Page
of 13